Eliquis Kit
Product Images NDC 0003-3764

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Eliquis (NDC 0003-3764). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by E.r. Squibb & Sons, L.l.c., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Apixaban Chemical Structure (Apixaban Struct)

Chemical structure of apixaban, the active ingredient in ELIQUIS. It depicts the molecular framework including multiple ring structures and functional groups characteristic of the compound.*

FDA Label Image

Eliquis 2.5 mg X 60s Bottle (Eliquis 2pt5mg 60slbl)

Eliquis (apixaban) tablets 2.5 mg film coated oral tablets label, containing 60 tablets. The label includes storage instructions, dosage form, and warnings, and lists the labelers as Bristol-Myers Squibb Company and Pfizer Inc. The product is marked for prescription use only and specifies not to use if the inner seal of the bottle is broken or missing.*

FDA Label Image

Eliquis 5 mg X 60s Bottle (Eliquis 5mg 60slbl)

Label for Eliquis (apixaban) tablets, 5 mg strength, film-coated oral tablets. The label indicates a 60 count package with NDC 0003-0894-21. It includes storage instructions, a barcode, manufacturer and marketer information including Bristol-Myers Squibb and Pfizer, and a note to dispense with medication guide.*

FDA Label Image

Aristotle Forest Plot (Eliquis Clin Forest Fig5)

A forest plot chart displaying the hazard ratios with 95% confidence intervals comparing Apixaban and Warfarin across various patient subgroups. The vertical line at hazard ratio 1 indicates no difference; points left favor Apixaban, right favor Warfarin. Subgroups include prior Warfarin status, age, sex, weight, prior stroke or TIA, diabetes, CHADS2 score, creatinine clearance, geographic region, and aspirin use at randomization, with event rates and patient numbers also provided.*

FDA Label Image

Aristotle Major Bleeding Forest Plot (Eliquis Forest Fig1)

A forest plot graph comparing the hazard ratio and 95% confidence intervals for apixaban versus warfarin across various patient subgroups. The x-axis represents hazard ratio values favoring apixaban or warfarin. Subgroups include age, sex, weight, prior stroke/TIA, diabetes status, CHADS2 score, creatinine clearance, geographic region, and aspirin randomization. Black dots represent hazard ratios with horizontal lines as confidence intervals.*

FDA Label Image

Aristotle Kaplan-meier Curve (Eliquis Km Fig4)

A Kaplan-Meier curve graph showing the proportion of subjects with stroke or systemic embolism over time (up to 36 months) for patients treated with ELIQUIS and Warfarin. The graph includes event counts and numbers at risk at various time points, comparing the two treatments with statistical values indicated.*

FDA Label Image

Effect Of Coadministered Drugs On Pharmacokinetics Of Apixaban (Eliquis Pkplot Drugs Fig2)

A pharmacokinetic chart showing the fold change and 90% confidence interval for the maximum concentration (Cmax) and area under the curve (AUC) of apixaban when given with interacting drugs. The chart lists combined P-gp and strong CYP3A4 inhibitors (Ketoconazole 400 mg, Clarithromycin 500 mg), other CYP3A4 and P-gp inhibitors (Diltiazem 360 mg, Naproxen 500 mg), and combined P-gp and strong CYP3A4 inducer (Rifampin 600 mg), with changes relative to reference on the x-axis ranging from 0.5 to 2.0.*

FDA Label Image

O:\e-submissions\pbo\products\eliquis 202155\08. Pas Esrd Dosing\01. Orig Submission\source\eliquis-pkplot-pop-fig3.jpg (Eliquis Pkplot Pop Fig3)

A pharmacokinetic chart depicting fold change and 90% confidence intervals of Cmax and AUC in various population subgroups relative to reference for Eliquis (apixaban). It includes data for renal impairment, age, body weight, and hepatic impairment along with dosing recommendations.*

FDA Label Image

Eliquis 5 mg X 74 Starter Pack Carton (Eliquis Starterpack 5mg74s Carton)

ELIQUIS 5 mg film-coated tablets 30-Day Starter Pack carton by E.R. Squibb & Sons, L.L.C. The pack contains 74 tablets in two wallets labeled for Days 1-14 and Days 15-30 for oral use. It specifies use for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and includes a medication guide and boxed warnings.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.